Literature DB >> 2635936

Thymectomy in myasthenia gravis. Results of 662 cases operated upon in 15 years.

G Maggi1, C Casadio, A Cavallo, R Cianci, M Molinatti, E Ruffini.   

Abstract

The results of thymectomy in the treatment of myasthenia gravis (MG) are reviewed in the light of a personal series of 662 MG patients, operated upon during the last 15 years. In 500 MG patients without thymoma, the following results have been achieved: remission 37.9%, improvement 49.4%, unchanged or worse 7.4%, dead 5.2%. There is no sex prevalence and the remission rate is higher in patients under 40 years of age (P less than 0.01), with mild disease (P less than 0.05), with a MG duration of less than 1 year (P less than 0.05) and with a follow-up length of between 5 and 10 years (P less than 0.01). No correlations are found between outcome and thymic histology. The results of 162 MG patients with thymoma are: remission rate 15.7%, improvement 60.3%, unchanged or worse 3.7% and dead 20.1%. The remission rate is higher with mild symptoms (P less than 0.05) and when the tumour is encapsulated (P less than 0.02). The postoperative mortality is 0.8% (none in the last 5 years) for non-thymomatous MG and 4.9% for thymomatous MG (2 of 8 patients died of pancytopaenia and 1 of pulmonary embolism).

Entities:  

Mesh:

Year:  1989        PMID: 2635936     DOI: 10.1016/1010-7940(89)90109-7

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  14 in total

1.  Limited upper sternotomy in general thoracic surgery.

Authors:  Marco Alifano; Sergio N Forti Parri; Walid Abu Arab; Barbara Bonfanti; Nicola Lacava; Calogero Porrello; Maurizio Boaron
Journal:  Surg Today       Date:  2008-03-27       Impact factor: 2.549

2.  Thymectomy for myasthenia gravis: what's next?

Authors:  Marc de Perrot; Laura Donahoe
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

3.  Effects of thymectomy on late-onset non-thymomatous myasthenia gravis: systematic review and meta-analysis.

Authors:  Jinwei Zhang; Yuan Chen; Hui Zhang; Zhaoyu Yang; Peng Zhang
Journal:  Orphanet J Rare Dis       Date:  2021-05-20       Impact factor: 4.123

4.  Definitions and standard indications of minimally-invasive techniques in thymic surgery.

Authors:  Marcin Zieliński
Journal:  J Vis Surg       Date:  2017-08-21

5.  Intravenous immunoglobulin for prophylaxis of acute exacerbation in Myasthenia Gravis.

Authors:  Mine Hayriye Sorgun; Huseyin Ozden Sener; Canan Yucesan; Nezih Yucemen
Journal:  Neurol Sci       Date:  2014-01-08       Impact factor: 3.307

6.  Surgical treatment of myasthenia gravis in two major Middle East teaching hospitals: factors influencing outcome.

Authors:  S A Hassantash; D G Ashbaugh; E D Verrier; R V Maier
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

7.  Thymectomy for Myasthenia Gravis: A 10-year Review of Cases at the Hospital Universiti Sains Malaysia.

Authors:  Julieana Muhammed; Chui Yin Chen; Wan Hazabbah Wan Hitam; Mohamad Ziyadi Ghazali
Journal:  Malays J Med Sci       Date:  2016-06-30

8.  Postoperative survival for patients with thymoma complicating myasthenia gravis-preliminary retrospective results of the ChART database.

Authors:  Fangrui Wang; Liewen Pang; Jianhua Fu; Yi Shen; Yucheng Wei; Lijie Tan; Peng Zhang; Yongtao Han; Chun Chen; Renquan Zhang; Yin Li; Keneng Chen; Hezhong Chen; Yongyu Liu; Youbing Cui; Yun Wang; Zhentao Yu; Xinming Zhou; Yangchun Liu; Yuan Liu; Zhitao Gu; Wentao Fang
Journal:  J Thorac Dis       Date:  2016-04       Impact factor: 2.895

9.  Treatment of myasthenia gravis based on its immunopathogenesis.

Authors:  Jee Young Kim; Kee Duk Park; David P Richman
Journal:  J Clin Neurol       Date:  2011-12-29       Impact factor: 3.077

10.  Incidence of thymoma in myasthenia gravis: a systematic review.

Authors:  Zhi-Feng Mao; Xue-An Mo; Chao Qin; Yong-Rong Lai; Maree L Hackett
Journal:  J Clin Neurol       Date:  2012-09-27       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.